• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why UiPath Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

    3/16/23 8:22:38 AM ET
    $AMRS
    $BUR
    $CPSH
    $CXAI
    Major Chemicals
    Industrials
    Finance: Consumer Services
    Finance
    Get the next $AMRS alert in real time by email

    Gainers

    • ThermoGenesis Holdings, Inc. (NASDAQ:THMO) rose 38.9% to $5.82 in pre-market trading. ThermoGenesis shares jumped around 99% on Wednesday after the company announced the roll out of ReadyStart cGMP Suites for early-stage cell and gene-therapy companies.
    • CXApp Holding Corp. (NASDAQ:CXAI) shares rose 38.3% to $5.67 in pre-market after dropping over 58% on Wednesday.
    • JanOne Inc. (NASDAQ:JAN) rose 26.7% to $1.80 in pre-market trading. JanOne announced that on March 9, 2023, that it entered into a stock purchase agreement with buyer VM7 Corporation.
    • Unique Fabricating, Inc. (NYSE:UFAB) rose 25% to $0.25 in pre-market trading.
    • Optex Systems Holdings, Inc. (NASDAQ:OPXS) rose 20.4% to $4.19 in pre-market trading after gaining 7% on Wednesday.
    • PureCycle Technologies, Inc. (NASDAQ:PCT) rose 17.6% to $5.61 in pre-market trading after the company issued Q4 update.
    • BiomX Inc. (NYSE:PHGE) rose 16.2% to $0.3499 in pre-market trading after jumping 10% on Wednesday. BiomX recently announced a $7.5 million private placement.
    • GSE Systems, Inc. (NASDAQ:GVP) rose 16.1% to $1.14 in pre-market trading after gaining 18% on Wednesday.
    • UiPath Inc. (NYSE:PATH) rose 14.6% to $16.78 in pre-market trading after the company reported better-than-expected Q4 results and issued strong revenue guidance.
    • RedHill Biopharma Ltd. (NASDAQ:RDHL) rose 8.5% to $0.1942 in pre-market trading.

    Losers

    • Esperion Therapeutics, Inc. (NASDAQ:ESPR) fell 50.3% to $1.98 in pre-market. In 8-K Filing Wednesday, Esperion reported partner Daiichi Sankyo Europe said Esperion is not entitled to receive milestone payments based on CLEAR outcomes data in trial of Bempedoic acid to treat cholesterol.
    • Virgin Orbit Holdings, Inc. (NASDAQ:VORB) fell 43.9% to $0.5670 in pre-market trading after CNBC said, ‘Virgin Orbit pauses operations for a week, furloughs nearly entire staff as it seeks funding.’
    • LivePerson, Inc. (NASDAQ:LPSN) shares fell 38.4% to $6.02 in pre-market trading after the company posted downbeat Q4 sales and issued weak revenue forecast.
    • ToughBuilt Industries, Inc.. (NASDAQ:TBLT) fell 18.8% to $1.51 in pre-market trading after reporting Q4 results.
    • Loyalty Ventures Inc. (NASDAQ:LYLT) fell 17.7% to $0.2230 in pre-market trading after jumping over 59% on Wednesday. Loyalty Ventures recently announced bankruptcy filings and plans to delist from the Nasdaq Global Select Market.
    • Amyris, Inc. (NASDAQ:AMRS) fell 17.7% to $0.98 in pre-market trading after posting a loss for the fourth quarter.
    • Proterra Inc. (NASDAQ:PTRA) fell 16.3% to $2.10 in pre-market trading after the company posted downbeat Q4 results and issued weak FY23 revenue forecast.
    • Burford Capital Limited (NYSE:BUR) shares dropped 14.5% to $6.54 in pre-market trading after the company issued an update on its 2022 business activity.
    • MMTec, Inc. (NASDAQ:MTC) fell 11% to $2.50 in pre-market trading after surging more than 35% on Wednesday.
    • CPS Technologies Corporation (NASDAQ:CPSH) shares fell 9% to $2.52 in pre-market trading. CPS Technologies recently posted Q4 EPS of $0.02.

    Now Read This: Insiders Selling Micron, KeyCorp And 2 Other Stocks

    Get the next $AMRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMRS
    $BUR
    $CPSH
    $CXAI

    CompanyDatePrice TargetRatingAnalyst
    Burford Capital Limited
    $BUR
    2/20/2026$14.00Outperform
    Wedbush
    Burford Capital Limited
    $BUR
    2/18/2026Buy
    BofA Securities
    Esperion Therapeutics Inc.
    $ESPR
    11/25/2025$9.00Overweight
    Piper Sandler
    PureCycle Technologies Inc.
    $PCT
    11/24/2025$9.00Buy → Hold
    TD Cowen
    CPS Technologies Corp.
    $CPSH
    11/13/2025$6.00Buy
    Roth Capital
    PureCycle Technologies Inc.
    $PCT
    10/22/2025$23.00Buy
    Seaport Research Partners
    UiPath Inc.
    $PATH
    10/2/2025$12.50 → $13.00Market Perform
    BMO Capital Markets
    UiPath Inc.
    $PATH
    9/5/2025$12.00Neutral
    DA Davidson
    More analyst ratings

    $AMRS
    $BUR
    $CPSH
    $CXAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cavoli Ivo James bought $5,127 worth of shares (1,500 units at $3.42), increasing direct ownership by 3% to 50,685 units (SEC Form 4)

    4 - CPS TECHNOLOGIES CORP/DE/ (0000814676) (Issuer)

    11/13/25 1:58:31 PM ET
    $CPSH
    Building Materials
    Consumer Discretionary

    Director Snow Daniel C bought $9,999 worth of shares (3,333 units at $3.00), increasing direct ownership by 39% to 11,941 units (SEC Form 4)

    4 - CPS TECHNOLOGIES CORP/DE/ (0000814676) (Issuer)

    10/9/25 3:30:59 PM ET
    $CPSH
    Building Materials
    Consumer Discretionary

    Director Hughes Francis J Jr bought $54,999 worth of shares (18,333 units at $3.00), increasing direct ownership by 4% to 438,009 units (SEC Form 4)

    4 - CPS TECHNOLOGIES CORP/DE/ (0000814676) (Issuer)

    10/9/25 3:26:54 PM ET
    $CPSH
    Building Materials
    Consumer Discretionary

    $AMRS
    $BUR
    $CPSH
    $CXAI
    SEC Filings

    View All

    SEC Form 10-K filed by Esperion Therapeutics Inc.

    10-K - Esperion Therapeutics, Inc. (0001434868) (Filer)

    3/10/26 4:55:11 PM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by CPS Technologies Corp.

    PRE 14A - CPS TECHNOLOGIES CORP/DE/ (0000814676) (Filer)

    3/10/26 4:36:20 PM ET
    $CPSH
    Building Materials
    Consumer Discretionary

    Esperion Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Esperion Therapeutics, Inc. (0001434868) (Filer)

    3/10/26 7:17:29 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRS
    $BUR
    $CPSH
    $CXAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Bogart Christopher P

    4 - Burford Capital Ltd (0001714174) (Issuer)

    3/9/26 4:44:46 PM ET
    $BUR
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by Chief Investment Officer Molot Jonathan Todd

    4 - Burford Capital Ltd (0001714174) (Issuer)

    3/9/26 4:43:35 PM ET
    $BUR
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by Chief Strategy Officer Oconnell Elizabeth

    4 - Burford Capital Ltd (0001714174) (Issuer)

    3/9/26 4:42:17 PM ET
    $BUR
    Finance: Consumer Services
    Finance

    $AMRS
    $BUR
    $CPSH
    $CXAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    – FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., March 10, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted co

    3/10/26 6:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UiPath Achieves AIUC-1 Certification, Setting New Standard for AI Agent Security and Reliability

    Agentic Automation leader becomes the first enterprise automation platform to meet independent verification standard for safe AI agent deployment UiPath (NYSE:PATH), a global leader in agentic automation, today announced it has achieved AIUC-1 certification, becoming the first enterprise automation platform to meet the world's reference standard for AI agent security and reliability. The certification, conducted by Schellman, the largest specialized cybersecurity auditor, validates that UiPath's AI agents operate safely and securely in real-world business environments. Created by the Artificial Intelligence Underwriting Company (AIUC) in partnership with security, risk, and legal expert

    3/9/26 4:30:00 PM ET
    $PATH
    Computer Software: Prepackaged Software
    Technology

    Substantial share purchases by Burford executive officers

    NEW YORK, March 9, 2026 /PRNewswire/ -- Burford Capital Limited ("Burford" or the "Company"), the leading global finance and asset management firm focused on law, provides the following notifications of various transactions by persons discharging managerial responsibilities (each, a "PDMR"), as well as a notification of its intention to purchase Burford's ordinary shares of nil par value ("Ordinary Shares") in connection with the Burford Capital Deferred Compensation Plan (the "Deferred Compensation Plan"). Investment by Executive Officers in Burford's Ordinary SharesOn March 5, 2026, certain executive officers used their respective cash compensation to invest in aggregate over $4.3 million

    3/9/26 9:45:00 AM ET
    $BUR
    Finance: Consumer Services
    Finance

    $AMRS
    $BUR
    $CPSH
    $CXAI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-16) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:30 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-17) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:37 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLETOL issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-13) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211616, Application Classification: Efficacy

    3/25/24 4:41:29 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRS
    $BUR
    $CPSH
    $CXAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush resumed coverage on Burford Capital with a new price target

    Wedbush resumed coverage of Burford Capital with a rating of Outperform and set a new price target of $14.00

    2/20/26 8:24:11 AM ET
    $BUR
    Finance: Consumer Services
    Finance

    BofA Securities initiated coverage on Burford Capital

    BofA Securities initiated coverage of Burford Capital with a rating of Buy

    2/18/26 9:36:48 AM ET
    $BUR
    Finance: Consumer Services
    Finance

    Piper Sandler initiated coverage on Esperion Therapeutics with a new price target

    Piper Sandler initiated coverage of Esperion Therapeutics with a rating of Overweight and set a new price target of $9.00

    11/25/25 8:41:48 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRS
    $BUR
    $CPSH
    $CXAI
    Leadership Updates

    Live Leadership Updates

    View All

    BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth

    Seasoned financial leaders join BiomX to support strategic execution and advancement of the companyDOVER, Del. and NESS ZIONA, Israel, March 9, 2026 /PRNewswire/ -- BiomX Inc. (NYSE:PHGE), a clinical-stage company developing natural and engineered phage therapies designed to target and destroy harmful bacteria in chronic diseases, today announced the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer. Oster brings extensive experience in corporate strategy, mergers and acquisitions, and operational leadership across capital-intensive industries including energy, infrastructure, and industrial sectors. Throughout his career, he has led complex

    3/9/26 9:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UiPath Set to Join S&P MidCap 400 and Versant Media Group to Join S&P SmallCap 600

    NEW YORK, Dec. 23, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600:  UiPath Inc. (NYSE:PATH) will replace Synovus Financial Corp. (NYSE:SNV) in the S&P MidCap 400 effective prior to the opening of trading on Friday, January 2. S&P MidCap 400 constituent Pinnacle Financial Partners Inc. (NASD: PNFP) is acquiring Synovus Financial Corp in a deal expected to be completed soon, pending final closing conditions.Versant Media Group Inc. (NASD: VSNT) will replace Brandywine Realty Trust (NYSE:BDN) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 6. S&P 500 constituent Comcast Corp. (NASD: CMCSA)

    12/23/25 5:55:00 PM ET
    $BDN
    $CMCSA
    $PATH
    Real Estate Investment Trusts
    Real Estate
    Cable & Other Pay Television Services
    Telecommunications

    Valerie Mars Appointed to PureCycle's Board of Directors

    ORLANDO, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- PureCycle Technologies, Inc. (NASDAQ:PCT), a U.S.-based company revolutionizing plastic recycling, announced today the appointment of Valerie Mars to its Board of Directors, effective January 1, 2026. Mars was previously the Senior Vice President and Head of Corporate Development at Mars, Incorporated, a function she led for over 20 years. Mars is a fourth-generation member of the Mars family, which founded Mars, Incorporated in 1911. She joined Mars in 1992 and spent more than three decades in the company before retiring at the end of 2024. Mars received her bachelor's degree from Yale University and a master's degree at the Columbia Busin

    12/18/25 8:00:00 AM ET
    $PCT
    Major Chemicals
    Industrials

    $AMRS
    $BUR
    $CPSH
    $CXAI
    Financials

    Live finance-specific insights

    View All

    Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    – FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., March 10, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted co

    3/10/26 6:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LivePerson to Announce Fourth Quarter 2025 Financial Results on March 12, 2026

    NEW YORK, March 4, 2026 /PRNewswire/ -- LivePerson, Inc. (NASDAQ:LPSN), a leading provider of predictable conversational AI, today announced the planned release of its fourth quarter financial results after the market close on Thursday, March 12, 2026. CEO John Sabino and CFO & COO John Collins will host a conference call later that day, at 5:00 p.m. Eastern Time. The conference call will be simulcast live and can be accessed by logging onto the investor relations section of the Company's web site at ir.liveperson.com.To participate via telephone, callers should dial in five to

    3/4/26 4:30:00 PM ET
    $LPSN
    Computer Software: Prepackaged Software
    Technology

    Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

    – Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth – – Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Potential Milestone Payments Tied to Certain Commercial and Regulatory Achievements – – Esperion to Host Conference Call on Tuesday, March 3, 2026 at 8:00 am ET – ANN ARBOR, Mich. and HENDERSON, Nev., March 03, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) and Corstasis Therapeutics Inc., a p

    3/3/26 6:00:00 AM ET
    $ESPR
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    $AMRS
    $BUR
    $CPSH
    $CXAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ToughBuilt Industries Inc.

    SC 13G/A - Toughbuilt Industries, Inc (0001668370) (Subject)

    11/14/24 7:29:15 PM ET
    $TBLT
    Industrial Machinery/Components
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by GSE Systems Inc.

    SC 13G/A - GSE SYSTEMS INC (0000944480) (Subject)

    11/14/24 7:13:40 PM ET
    $GVP
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by LivePerson Inc.

    SC 13G/A - LIVEPERSON INC (0001102993) (Subject)

    11/14/24 5:21:06 PM ET
    $LPSN
    Computer Software: Prepackaged Software
    Technology